485 related articles for article (PubMed ID: 25958815)
21. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
22. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
23. Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.
Magwenyane AM; Ugbaja SC; Amoako DG; Somboro AM; Khan RB; Kumalo HM
Comput Math Methods Med; 2022; 2022():2147763. PubMed ID: 35685897
[TBL] [Abstract][Full Text] [Related]
24. Heat shock proteins in cancer: targeting the 'chaperones'.
Nahleh Z; Tfayli A; Najm A; El Sayed A; Nahle Z
Future Med Chem; 2012 May; 4(7):927-35. PubMed ID: 22571616
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
26. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
27. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
28. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
29. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
30. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
32. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
33. Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.
Ren J; Li J; Wang Y; Chen W; Shen A; Liu H; Chen D; Cao D; Li Y; Zhang N; Xu Y; Geng M; He J; Xiong B; Shen J
Bioorg Med Chem Lett; 2014 Jun; 24(11):2525-9. PubMed ID: 24751441
[TBL] [Abstract][Full Text] [Related]
34. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
[TBL] [Abstract][Full Text] [Related]
35. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
[TBL] [Abstract][Full Text] [Related]
36. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
Bussenius J; Blazey CM; Aay N; Anand NK; Arcalas A; Baik T; Bowles OJ; Buhr CA; Costanzo S; Curtis JK; DeFina SC; Dubenko L; Heuer TS; Huang P; Jaeger C; Joshi A; Kennedy AR; Kim AI; Lara K; Lee J; Li J; Lougheed JC; Ma S; Malek S; Manalo JC; Martini JF; McGrath G; Nicoll M; Nuss JM; Pack M; Peto CJ; Tsang TH; Wang L; Womble SW; Yakes M; Zhang W; Rice KD
Bioorg Med Chem Lett; 2012 Sep; 22(17):5396-404. PubMed ID: 22877636
[TBL] [Abstract][Full Text] [Related]
37. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
Prodromou C
Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
[TBL] [Abstract][Full Text] [Related]
38. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
Workman P
Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
[TBL] [Abstract][Full Text] [Related]
40. HSP90: a rising star on the horizon of anticancer targets.
Dai C; Whitesell L
Future Oncol; 2005 Aug; 1(4):529-40. PubMed ID: 16556029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
